Lonza to Patent Key Ingredient in ResistAid for Adaptive Immune Response
The patent relates to LAG’s positive effect on the adaptive arm of the immune system prior to, during, and after exposure to foreign antigens.
Lonza announced it has filed a patent application for larch arabinogalactan (LAG), the key component in Lonza’s ResistAid immune-health ingredient, and its role in enhancing adaptive immune response. The application has been published by the World Intellectual Property Organization.
The patent relates to LAG’s positive effect on the adaptive arm of the immune system prior to, during, and after exposure to foreign antigens. The application also claims potential use in a vaccination kit comprising a composition of arabinogalactan and a vaccine.
“As the critical component in Lonza’s ResistAid, LAG has demonstrated a distinct positive immunomodulatory effect, selectively enhancing the immune system in response to antigenic stimulation,” says Bryan Rodriguez, Lonza’s technical marketing and scientific affairs manager. “This immunomodulatory approach, as opposed to over-stimulation (or hypersensitivity), helps prevent potential damage to the host cells.”
Last year, a study on this effect was published in Nutrition Journal.
